Glaucoma Research Foundation to Host Third Annual Glaucoma 360 New Horizons Forum in February

By


SAN FRANCISCO—The Glaucoma Research Foundation has announced its third annual Glaucoma 360 New Horizons Forum, scheduled to take place here on Feb. 7, 2014 at the Palace Hotel. The New Horizons Forum is the main event of a three-part series scheduled here from Feb. 6 to Feb. 8 with the goal of promoting the development of new and more effective therapies and diagnostics for glaucoma patients.

Glaucoma 360 was founded by Glaucoma Research Foundation Board of Directors Adrienne Graves, PhD and Andrew G. Iwach, MD who also serve as co-chairs for the events.

According to the Foundation, attendees and speakers of Glaucoma 360 include national and international leaders in medicine, science, business, venture capital and the FDA. The Forum will include industry panel discussions as well as presentations on the latest glaucoma developments and topics such as reimbursement, funding opportunities and building strategic partnerships to advance innovation in the field.

The New Horizons Forum keynote address, also known as the Drs. Henry and Frederick Sutro Memorial Lecture, will be delivered by chairman and director of the Shiley Eye Center, University of California, San Diego, Robert N. Weinreb, MD.

“We are showcasing early-stage companies who are developing new glaucoma drugs, devices and drug delivery systems,” said Graves. “By putting them together with venture capitalists, industry executives, FDA leaders and clinicians, we hope to stimulate and facilitate key discussions and connections. It's a way for the Glaucoma Research Foundation to serve as a catalyst in the development of new glaucoma therapies."

Iwach, the Foundation’s Board Chair and executive director at the Glaucoma Center of San Francisco, added, “It is a changing field, and we are delighted and honored that we are able to assemble such an accomplished group, all dedicated to new developments in glaucoma.”

Presenting companies include AßSee; AcuMEMS, Inc.; Aerie Pharmaceuticals, Inc.; Amakem Therapeutics; Amorphex Therapeutics LLC; AqueSys, Inc.; CheckedUp; ClearSide Biomedical, Inc.; Envisia Therapeutics; Glaukos Corporation; GrayBug; iCare USA; InnFocus, Inc.; Kala Pharmaceuticals; Keep Your Sight; Ocular Therapeutix, Inc.; Ono Pharmaceutical Co., LTD; pSivida; SKS Ocular LLC; Solx, Inc.; SwissMicro Technology; Transcend Medical; and Zordera.

Glaucoma 360 will also include a Gala on Feb. 6, 2014 honoring William J. Link, PhD, a leading venture capitalist and entrepreneur specializing in ophthalmology, and singer-songwriter, Judy Collins, as well as a continuing medical education program for clinicians, said the Glaucoma Research Foundation. All proceeds from the series will support the Glaucoma Research Foundation’s research and education programs.

A detailed list of additional speakers, panelists and discussion leaders is available on the glaucoma.org website. For more information, contact Andrew Jackson, director of communications, at (415) 986-3162 or ajackson@glaucoma.org.